Clinical Trial Update: Dapagliflozin With or Without Spironolactone for HFpEF [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update evaluating dapagliflozin with or without spironolactone for heart failure with preserved ejection fraction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• Spironolactone (spironolactone)

Snippet

Sponsor: Universidade do Porto | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2, Phase 3 | Status: COMPLETED